medigraphic.com
SPANISH

Cirugía y Cirujanos

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2013, Number 4

<< Back Next >>

Cir Cir 2013; 81 (4)

Carcinosarcoma of the breast a rare entity with fatal prognosis. One case report

Villalón-López JS, Souto-del Bosque R, Alonso-Briones MV, Trujillo-de Anda AP
Full text How to cite this article

Language: Spanish
References: 19
Page: 328-332
PDF size: 328.97 Kb.


Key words:

carcinosarcoma, breast cancer, cancer, metaplastic breast carcinoma.

ABSTRACT

Background: breast metaplastic carcinomas are a heterogeneous group of neoplasms that exhibit a poor prognosis compared with invasive ductal carcinoma. Correspond less than 1% of all malignant neoplasms of the mammary gland. They usually present as high-grade tumors with a lower rate of lymph node metastases and decreased expression of estrogen and progesterone receptors and Her2 and increased expression of Her1 and Ki-67.
Clinical case: we report a 52 year old woman with a breast carcinosarcoma presented with a left breast tumor fungated, ulcerated, polypoid and 18 cm in major diameter with lymph node metastases at diagnosis. She received multimodal management with neoadjuvant chemotherapy, followed by mastectomy and adjuvant chemotherapy; she presented progression of the disease with lung metastases and local massive recurrence, eventually died from complications associated to the disease.
Conclusions: metaplastic carcinomas of the breast are extremely rare entities. Due the nature of disease and presentation, the prognosis is poor in these patients. There are several histologic subtypes based on studies of hematoxylin and eosin and immunohistochemical stains. It requires multimodal therapy (surgery, radiotherapy and chemotherapy) for best results.


REFERENCES

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.

  2. Perfil Epidemiológico de los Tumores Malignos en México. Centro Nacional de Vigilancia Epidemiológica y Control de Enfermedades. (consultado el 20 julio 2012). Disponible en: http://www.dgepi. salud.gob.mx/2010/PDFS/PUBLICACIONES/MONOGRAFIAS/ PEPID_TUMORES_MALIGNOS_MEX_2010.pdf

  3. Tzu-Chieh C, Chia-Siu W, Shin-Cheh C, Miin-Fu C. Metaplastic carcinomas of the breast. J Surg Oncol 1999;71:220-225.

  4. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 1989;20:628-635.

  5. Wargotz ES, Does PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol 1989;20:732-740.

  6. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 1989;64:1490-1499.

  7. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 1990;65:272-276.

  8. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 1990;21:1142-1150.

  9. Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 2010;120:627-637.

  10. Lim KH, Oh DY, Chie EK, Han W, Sa Im, Kim TY, et al. Metaplastic breast carcinoma: Clinicopathologic features and prognostic value of triple negativity. Jpn J Clin Oncol 2010;40:112-118.

  11. Leibl S, Moinfar F. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol 2005;58:700-704.

  12. Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005;7:R1028-R1035.

  13. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base. Ann Surg Oncol 2007;14:166-173.

  14. Esses KM, Hagmaier RM, Blanchard SA, Lazarchick JJ, Riker AI. Carcinosarcoma of the breast: two case reports and review of the literature. Cases J 2009;2:15.

  15. Patterson SK, Tworek JA, Roubidoux MA, Helvie MA, Oberman HA. Metaplastic carcinoma of the breast: mammographic appearance with pathologic correlation. AJR Am J Roentgenol 1997;169:709- 712.

  16. Günham-Bilgen I, Memis A, Ûstün EE, Zekioglu O, Özdemir N. Metaplastic Carcinoma of the Breast: Clinical, Mammographic, and Sonographic Findings with Histopathologic Correlation. AJR Am J Roentgenol 2002;178:1421-1425.

  17. Velasco M, Santamaría G, Ganau S, Farrús B, Zanón G, Romagosa C, et al. MRI of Metaplastic Carcinoma of the Breast. AJR Am J Roentgenol 2005;184:1274-1278.

  18. Tseng WH, Martinez SR. Metaplastic Breast Cancer: To Radiate or Not to Radiate? Ann Surg Oncol 2011;18:94-103.

  19. Dave G, Cosmatos H, Do T, Lodin K, Varshney D. Metaplastic carcinoma of the breast: A retrospective review. Int J Radiat Oncol Biol Phys 2006:64:771-775.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Cir Cir. 2013;81